Thyroid Function in Children and Adolescents With Idiopathic Growth Hormone (GH) Deficiency After Initiation of Therapy With Recombinant GH
Authors' conclusion
The findings of our study are consistent with most previous studies, confirming that rGH therapy in children with GHD induces a modest, statistically significant decline in FT4 while maintaining stable TSH. FT4 was associated with the increase of IGF-1 SD score during rGH therapy while the addition of SPINA-GT evaluation supports the preservation of the thyroid secretory reserve during the first year of rGH treatment.
Study context
- Population
- Children with idiopathic GH deficiency (GHD) treated with recombinant GH (rGH); baseline median age 10.0 years, 84% prepubertal
- Participants
- 111 children
- Outcome
- Longitudinal thyroid function changes and thyroid secretory capacity (SPINA-GT) over the first year of rGH therapy
- Follow-up
- 12 months
Methodological detailssingle tertiary center
- Single tertiary center
Main finding
As reported in the abstract
- IGF-1 levels significantly increased
- P < .001
- Free T4 (FT4) levels modestly declined
- P = .008
Observational data: associations, not effects.
Further findings
Mixed-effects modeling
- FT4 associated with IGF-1 SD score
- P < 0.001
- Thyroid-stimulating hormone (TSH) not associated with any covariate
Original publication
Thyroid Function in Children and Adolescents With Idiopathic Growth Hormone (GH) Deficiency After Initiation of Therapy With Recombinant GH. Endocr Pract. Published 11 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →